Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Obesity and cardiovascular risk].

M Krempf1, M Farnier

  • 1Clinique d'Endocrinologie, Hôtel-Dieu, 44093 Nantes. mkrempf@sante.univ-nantes.fr

Annales D'Endocrinologie
|January 15, 2002
PubMed
Summary

Losing even 10% of body weight significantly improves cardiovascular risk factors in overweight and obese individuals. Lifestyle changes are primary, with medication like orlistat considered if needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients.

Diabetes & metabolism·2020
Same author

Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption.

International journal of obesity (2005)·2017
Same author

[Screening for disturbed eating behavior in adolescents with type 1 diabetes].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2017
Same author

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Annales de cardiologie et d'angeiologie·2017
Same author

Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?

Diabetes & metabolism·2017
Same author

Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2014

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Syndrome

Context:

  • Overweight and obesity increase cardiovascular disease (CVD) risk and mortality.
  • Visceral fat distribution is linked to insulin resistance and metabolic syndrome X.
  • Obesity often coexists with CVD risk factors like type 2 diabetes, hypertension, and dyslipidemia.

Purpose:

  • To review the impact of weight reduction on cardiovascular risk factors in overweight and obese patients.
  • To evaluate the role of lifestyle interventions and pharmacological treatments, including orlistat, in managing obesity-related risks.

Summary:

  • Weight reduction, even moderate (10%), improves cardiovascular risk factors and overall vascular risk.
  • Nutritional and hygienic measures (diet, physical activity) are the cornerstone of weight management.
  • Pharmacological treatment, such as orlistat, may be considered when lifestyle changes are insufficient, showing benefits in glycemic control and hypertension.

Impact:

  • Weight loss interventions effectively reduce major cardiovascular risk factors.
  • Orlistat demonstrates efficacy in improving metabolic abnormalities and cardiovascular risk factors in overweight/obese patients, particularly those with type 2 diabetes and hypertension.

Related Experiment Videos